Braveheart Bio (NASDAQ:BRVE) Shares Gap Up – Still a Buy?

Braveheart Bio, Inc. (NASDAQ:BRVE) gapped up prior to trading on Monday. The stock had previously closed at $17.42, but opened at $19.08. Braveheart Bio shares last traded at $18.96, with a volume of 3,487 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus began coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 target price for the company. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. Weiss Ratings began coverage on shares of Braveheart Bio in a research report on Monday, November 2nd. They set a “sell (d-)” rating on the stock. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Braveheart Bio in a report on Tuesday, October 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Braveheart Bio Price Performance

The company has a market capitalization of $1.79 billion and a price-to-earnings ratio of -7.81. The stock has a 50-day simple moving average of $22.72.

Braveheart Bio (NASDAQ:BRVE) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, equities research analysts predict that Braveheart Bio, Inc. will post -1.99 EPS for the current fiscal year.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.